Bindinglaw

US · guidance

CMS SOM App. C, Tag D5687

§493.1276(d) The laboratory report must include a summary and interpretation of

activein force · 2026-07-22 – presentas-observed

the observations, number of cells counted and analyzed, and use the International

System for Human Cytogenetic Nomenclature.

Probes §493.1276(d)

Does the laboratory report include:

• Type of banding method used, if applicable;

• Stage of cell mitosis when banded;

• Number of cells counted and analyzed microscopically;

• Number of cells from which photographic or computerized karyotypes were

prepared; and

• Estimate of the banding resolution achieved?

Does the laboratory, where appropriate, ensure that FISH clinical interpretations are

made in conjunction with standard cytogenetic analyses and evaluated against patient

medical history and other diagnostic test results?

Preliminary reports of karyotypes based on less than full analysis are acceptable if the

diagnosis is clear.

For what types of cultures are preliminary reports issued? These may include, but are not

limited to, the following:

• Bone marrow analysis (within 14 days);

• Unstimulated blood cultures (within 14 days); and

• Lymphocytes from newborns (within 7 days).

What is the average length of time for reporting? (Use D5801 or D5815, as appropriate):

• Amniotic fluid cell cultures (90% of prenatal diagnosis cases should be signed out

in 21 days);

• Routine lymphocyte cultures (approximately 4-5 weeks); and

• Fibroblast cultures (approximately 2-3 months)?

Do records document:

• Observations made concurrently with the performance of each step in the

examination of specimens/cultures? (Use D5683); and

• The number of cases reviewed, signed out and/or the frequency of failed or sub-optimal cultures?

§493.1276 Standard: Clinical cytogenetics.

§493.1276 (e) The laboratory must document all control procedures performed, as

specified in this section.

Probes §493.1276(e)

Each day of use, does the laboratory test the positive and negative reactivity of staining

materials to ensure predictable staining characteristics? Use D5473.

Does the laboratory, concurrent with the initial use, check each batch of media for pH

(amniotic cell cultures should be kept between pH 6.8 and 7.8), sterility, and ability to

support growth? Use D5477.

Does the laboratory employ an alternative procedure for the immediate assessment and

monitoring of all testing over time? For example: Control materials are not routinely

available to demonstrate chromosome abnormalities for linkage, breakage, or

translocation, but the laboratory must demonstrate an alternative mechanism for detecting

chromosome abnormalities to be analyzed. Use D5485.

An alternative procedure might include split sample with another laboratory, repeat

patient specimen, special stains, FISH assays, and/or molecular assays.

History

Rev. 233; Issued: 09-12-25; Effective: 09-12-25; Implementation: 09-12-25

Provenance

Source
cms.gov
Retrieved
2026-07-22
Edition
som-2026-07-22
Content hash
1497053849000f5f2410df8ab225d0b27e0f650a8b7afbbe96d92781b03a0237
View the official source →

The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.

Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.

Coverage · API docs

Bindinglaw

Point-in-time US law with the receipt attached. Source URL, retrieval time, content hash, and validity dates on every answer.

curl api.binding.law/v1/law/coverage

© 2026 binding.law · a Jubal, Inc. productAttorneys and firms never pay. Ever.